Premier provider of seed and early stage venture capital to healthcare companies.
Partners & invests in best-in-class innovative biotherapeutic & medtech entrepreneurs building transformative companies.
Applying human ingenuity to help you elevate cancer care.
Investing in and supporting the global entrepreneurial community to solve critical healthcare needs.
Specializes in early and mid-stage life science companies. We are interested in innovative technologies in therapeutics, diagnostics and medical devices.
Helps entrepreneurs define, develop, grow, and build value in their businesses, principally in medicine healthcare technology.
Investing in promising new ventures in emerging technologies with high growth potential.
Provides early stage venture capital to promising entrepreneurial companies in healthcare technology and other fields.
Building transformational human medicine companies that benefit patients and the professionals who serve them.
Ready to learn more about us?
Connect with the HistoSonics team.
Last updated on April 10, 2024
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.
